Lenalidomide and pomalidomide modulate hematopoietic cell expansion and differentiation in the presence of MSC
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Hematology"
DOI: 10.1007/s12185-024-03815-y
Abstract: Cytopenia is a well-documented complication in the treatment of hematological malignancies with lenalidomide and pomalidomide. Although prior studies have highlighted direct effects on hematopoietic cells to explain this adverse effect, the involvement of hematopoietic-supportive stroma… read more here.
Keywords: differentiation; expansion differentiation; presence; cd34 ... See more keywords
Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergizein vitroand potentiatein vivoanti-tumor activity in multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-6711
Abstract: Multiple myeloma (MM) is a hematological malignancy that affects plasma cells and leads to devastating clinical features. Typically, front-line and relapsed/refractory multiple myeloma (RRMM) treatments comprise standard of care (SOC) combinations that include proteasome inhibitors… read more here.
Keywords: lenalidomide pomalidomide; multiple myeloma; belantamab mafodotin; cell ... See more keywords